References

1. Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, Shimabe M, Mukai M, Watanabe R, Morishige T. (2021) A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Clin Pharmacol Drug Dev, 10 (8): 870-883. [PMID:33512065]

2. Furue M, Furue M. (2021) OX40L-OX40 Signaling in Atopic Dermatitis. J Clin Med, 10 (12): 2578. [PMID:34208041]

3. Kierkus J, Pesegova M, Klopocka M, Brankovic M, Kasai N, Efuni S, Kong J, Nakajima Y, Jordan C, Matsui T et al.. (2020) Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis. Crohns Colitis 360, 2 (3): otaa049. [PMID:36776497]

4. Nakagawa H, Iizuka H, Nemoto O, Shimabe M, Furukawa Y, Kikuta N, Ootaki K. (2020) Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci, 99 (2): 82-89. [PMID:32651105]

5. Papp KA, Gooderham MJ, Girard G, Raman M, Strout V. (2017) Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol, 31 (8): 1324-1332. [PMID:28556418]